Fate Therapeutics Inc (FATE)

[jondoeuk]

They knockout SOCS1, CISH, BIM and FAS. Nothing about the proprietary signal converter or design of the CAR. As for HLA-E, it makes little sense to me as 50-90% of the human population are CMV+ (NKG2C+ adaptive NKs target HLA-E+ cells) https://onlinelibrary.wiley.com/doi/10.1002/rmv.2034

Also, work on iPSC-derived ab T-cells is ongoing.